Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis
- Univ. of California, Davis, CA (United States). Division of Nephrology, Dept. of Internal Medicine
- Univ. of Kansas, Lawrence, KS (United States). Medical Center, Kidney Inst., Dept. of Internal Medicine
- Division of Nephrology, Department of Medicine, Washington University, St. Louis, Missouri
- Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
- Washington Univ., St. Louis, MO (United States). Division of Nephrology, Dept. of Medicine
- Univ. of California, Davis, CA (United States). Dept. of Pathology
- Univ. of California, Davis, CA (United States). West Coast Metabolomics Center
- Univ. of California, Davis, CA (United States). Division of Nephrology, Dept. of Internal Medicine; Univ. of California, Davis, CA (United States). Dept. of Pathology; VA Northern California Health Care System, Sacramento, CA (United States). Medical Service
Research into metabolic reprogramming in cancer has become commonplace, yet this area of research has only recently come of age in nephrology. In light of the parallels between cancer and autosomal dominant polycystic kidney disease (ADPKD), the latter is currently being studied as a metabolic disease. In clear cell renal cell carcinoma (RCC), which is now considered a metabolic disease, we and others have shown derangements in the enzyme arginosuccinate synthase 1 (ASS1), resulting in RCC cells becoming auxotrophic for arginine and leading to a new therapeutic paradigm involving reducing extracellular arginine. Based on our earlier finding that glutamine pathways are reprogrammed in ARPKD, and given the connection between arginine and glutamine synthetic pathways via citrulline, we investigated the possibility of arginine reprogramming in ADPKD. Here, we now show that, in a remarkable parallel to RCC, ASS1 expression is reduced in murine and human ADPKD, and arginine depletion results in a dose-dependent compensatory increase in ASS1 levels as well as decreased cystogenesis in vitro and ex vivo with minimal toxicity to normal cells. Nontargeted metabolomics analysis of mouse kidney cell lines grown in arginine-deficient versus arginine-replete media suggests arginine-dependent alterations in the glutamine and proline pathways. Thus, depletion of this conditionally essential amino acid by dietary or pharmacological means, such as with arginine-degrading enzymes, may be a novel treatment for this disease.
- Research Organization:
- Lawrence Livermore National Laboratory (LLNL), Livermore, CA (United States)
- Sponsoring Organization:
- USDOE National Nuclear Security Administration (NNSA)
- Grant/Contract Number:
- AC52-07NA27344
- OSTI ID:
- 1502039
- Report Number(s):
- LLNL-JRNL--734198; 886144
- Journal Information:
- American Journal of Physiology-Renal Physiology, Journal Name: American Journal of Physiology-Renal Physiology Journal Issue: 6 Vol. 315; ISSN 1931-857X
- Country of Publication:
- United States
- Language:
- English
A high-throughput screening platform for Polycystic Kidney Disease (PKD) drug repurposing utilizing murine and human ADPKD cells
|
journal | March 2020 |
TLR4 knockout can improve dysfunction of β-cell by rebalancing proteomics disorders in pancreas of obese rats
|
journal | October 2019 |
Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course
|
journal | February 2019 |
Similar Records
Mitochondrial Sirt3 supports cell proliferation by regulating glutamine-dependent oxidation in renal cell carcinoma
Down-regulation of PKHD1 induces cell apoptosis through PI3K and NF-{kappa}B pathways